Table 1.

Treatment Administration, by Study Component

Phase I Component
Dose Level		Sorafenib (twice daily)		Bevacizumab (every 2 weeks)
+2		400 mg BID		5 mg/kg
+1		400 mg BID		2.5 mg/kg
0*		400 mg BID		1.25 mg/kg
−1		400 mg BID, 5 consecutive days out of each 7 days		1.25 mg/kg
(−2a)		200 mg BID days 1–28		2.5 mg/kg
−2		200 mg BID days 1–28		1.25 mg/kg
(−3b)		200 mg BID, days 1–5 out of each 7 days		5 mg/kg
(−3a)		200 mg BID, days 1–5 out of each 7 days		2.5 mg/kg
−3		200 mg BID, days 1–5 out of each 7 days		1.25 mg/kg
Phase II Component
Agent	Dose Level	Route	Day	ReRx
Arm A
Bevacizumab	2.5 mg/kg	IV*	Day 1, 15(+/− 3 days)	Every 4 weeks
Sorafenib	200 mg BID	PO	Days 1–28
Arm B
Sorafenib	400 mg BID	PO	Days 1–28	Every 4 weeks

^*Starting dose level